Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00037869 · ClinicalTrials.gov registry record · Phase 3
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
NCT00037869: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00037869 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00037869, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if I-131 Metaiodobenzylguanidine (MIBG) can shrink or slow the growth of the tumor(s) in patients with metastatic neuroendocrine tumors. The safety of this treatment will also be studied.
Interventions
- DRUG I-131 Metaiodobenzylguanidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2001-11 |
| Est. Completion | 2005-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00037869
The ClinicalTrials.gov registry entry for NCT00037869 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which I-131 Metaiodobenzylguanidine is the first listed.
NCT00037869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00037869 about?
NCT00037869 is a clinical study titled "High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors". The goal of this clinical research study is to learn if I-131 Metaiodobenzylguanidine (MIBG) can shrink or slow the growth of the tumor(s) in patients with metastatic neuroendocrine tumors. The safety of this treatment will also be studied.
What is the current status of trial NCT00037869?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2001-11. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00037869?
The interventions under investigation include: I-131 Metaiodobenzylguanidine (DRUG).
Who is sponsoring clinical trial NCT00037869?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.